港股異動 | 藥明生物(2269.HK)漲逾5% 有望入選恆指成份股
格隆匯8月13日丨藥明生物(2269.HK)漲逾5%,報163.9港元,總市值2224.6億港元。週五盤後,恆生指數公司將公佈恆生系列指數季度定期審議結果,其中便包括港股市場旗艦指數,如恆生和國企指數。中金公司發文稱,初步測算,阿里巴巴、美團點評、安踏體育、阿里健康、藥明生物、華潤啤酒排在恆生指數選擇順位前列。阿里巴巴漲近2%,華潤啤酒漲0.58%。藥明生物此前發佈公告稱,集團預期截至2020年6月30日止六個月所錄得的歸屬於公司權益股東的利潤相比於去年同期歸屬於公司權益股東的利潤增長58%以上。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.